Grass pollen allergy immunotherapy - Leti Pharma

Drug Profile

Grass pollen allergy immunotherapy - Leti Pharma

Alternative Names: Depigoid 34% GrassesMix/33% olea europaea/33% salsola kali; Depigoid Grass Mix; Depigoid Phleum pratense; Depigoid® Phleum; Modified allergen extract of Phleum pratense

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratorios LETI; LETI Pharma GmbH
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinoconjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 01 Aug 2016 LETI Pharma completes a phase II trial for Allergic conjunctivitis and Allergic rhinitis in Poland (EudraCT2014-004732-19)
  • 11 May 2016 An investigator completes a a phase II trial for Seasonal allergic rhinitis in Spain (SC) (EudraCT2010-020949-26)
  • 01 Aug 2015 Laboratorios LETI terminates a phase II trial in Seasonal allergic rhinitis and Allergic conjunctivitis in Spain (EudraCT2014-001571-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top